ANI Pharmaceuticals, Inc.ANIPNASDAQ
LOADING
|||
Revenue Growth Accelerating
Growth above historical average with positive momentum
Left:
||||
Year-over-year revenue growth rate
Latest
7.78%
↑ 14% above average
Average (39q)
6.85%
Historical baseline
Range
High:52.45%
Low:-10.81%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 7.78% |
| Q2 2025 | 7.23% |
| Q1 2025 | 3.44% |
| Q4 2024 | 28.48% |
| Q3 2024 | 7.46% |
| Q2 2024 | 0.44% |
| Q1 2024 | 4.39% |
| Q4 2023 | -0.13% |
| Q3 2023 | 13.11% |
| Q2 2023 | 9.14% |
| Q1 2023 | 13.32% |
| Q4 2022 | 12.42% |
| Q3 2022 | 13.49% |
| Q2 2022 | 14.54% |
| Q1 2022 | 5.82% |
| Q4 2021 | 17.03% |
| Q3 2021 | 7.07% |
| Q2 2021 | -10.81% |
| Q1 2021 | -4.77% |
| Q4 2020 | 8.07% |
| Q3 2020 | 9.30% |
| Q2 2020 | -2.62% |
| Q1 2020 | 3.77% |
| Q4 2019 | -6.57% |
| Q3 2019 | -5.56% |
| Q2 2019 | 2.78% |
| Q1 2019 | -7.41% |
| Q4 2018 | 12.66% |
| Q3 2018 | 7.27% |
| Q2 2018 | 1.69% |
| Q1 2018 | -1.70% |
| Q4 2017 | -1.82% |
| Q3 2017 | 7.60% |
| Q2 2017 | 22.21% |
| Q1 2017 | -4.13% |
| Q4 2016 | -0.83% |
| Q3 2016 | 22.94% |
| Q2 2016 | 52.45% |
| Q1 2016 | 13.97% |
| Q4 2015 | -9.70% |